tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2024 Dec 31;20(1):2416329.
doi: 10.1080/21645515.2024.2416329. Epub 2024 Oct 24. A prospective, randomized, parallel, active controlled, phase III Indian study of immunogenicity and safety of two inactivated influenza vaccines - Vaxiflu-4 and Fluarix tetra in children aged 6 months to 35 months
Kairav Kothari[SUP] 1 [/SUP], Shreyansh Shah[SUP] 2 [/SUP], Vinay Kumar Gill[SUP] 3 [/SUP], Rajib Kumar Ray[SUP] 4 [/SUP], N Ravi Kumar[SUP] 5 [/SUP], Jayesh Sanmukhani[SUP] 6 [/SUP], Pavankumar Daultani[SUP] 6 [/SUP], Ravindra Mittal[SUP] 6 [/SUP], Trayambak Dutta[SUP] 7 [/SUP], Manish Mahajan[SUP] 8 [/SUP], Samir Desai[SUP] 9 [/SUP]
Affiliations
Influenza is highly prevalent in children under five years, particularly those under two, accounting for 5-10% of acute respiratory infections (ARIs) in India. This study was conducted to compare the immunogenicity and safety of two tetravalent inactivated influenza vaccines in healthy children aged 6-35 months. The dose recommendation for this group increased from 0.25 mL to 0.5 mL to ensure adequate immune response, as per the Advisory Committee on Immunization Practices. This Phase III, randomized, single-blind, active-controlled, multicentre study was conducted from May to October 2022 across five centers in India. A total of 346 subjects were randomized to receive two doses of either the test vaccine (Vaxiflu-4, Zydus Lifesciences Limited; n = 174) or the reference vaccine (Fluarix Tetra, GlaxoSmithKline; n = 172). The primary objective was to compare immunogenicity using seroprotection rate, seroconversion rate, and geometric mean titers (GMTs) against four vaccine strains. Safety profiles were also compared. Both vaccines demonstrated non-inferiority, with seroprotection rates over 95%, seroconversion rates above 90%, and significant GMT increases. Adverse events (AEs) were similar for both vaccines, including pain at the injection site, erythema, swelling, and pyrexia. The test vaccine, Vaxiflu-4, showed non-inferiority in terms of immunogenicity and safety when compared with reference vaccine, Fluarix Tetra (Clinical trial registry number: CTRI/2022/05/042514).
Keywords: Immunogenicity; Influenza; pediatric vaccination; safety profile; tetravalent inactivated vaccine.
. 2024 Dec 31;20(1):2416329.
doi: 10.1080/21645515.2024.2416329. Epub 2024 Oct 24. A prospective, randomized, parallel, active controlled, phase III Indian study of immunogenicity and safety of two inactivated influenza vaccines - Vaxiflu-4 and Fluarix tetra in children aged 6 months to 35 months
Kairav Kothari[SUP] 1 [/SUP], Shreyansh Shah[SUP] 2 [/SUP], Vinay Kumar Gill[SUP] 3 [/SUP], Rajib Kumar Ray[SUP] 4 [/SUP], N Ravi Kumar[SUP] 5 [/SUP], Jayesh Sanmukhani[SUP] 6 [/SUP], Pavankumar Daultani[SUP] 6 [/SUP], Ravindra Mittal[SUP] 6 [/SUP], Trayambak Dutta[SUP] 7 [/SUP], Manish Mahajan[SUP] 8 [/SUP], Samir Desai[SUP] 9 [/SUP]
Affiliations
- PMID: 39445787
- DOI: 10.1080/21645515.2024.2416329
Influenza is highly prevalent in children under five years, particularly those under two, accounting for 5-10% of acute respiratory infections (ARIs) in India. This study was conducted to compare the immunogenicity and safety of two tetravalent inactivated influenza vaccines in healthy children aged 6-35 months. The dose recommendation for this group increased from 0.25 mL to 0.5 mL to ensure adequate immune response, as per the Advisory Committee on Immunization Practices. This Phase III, randomized, single-blind, active-controlled, multicentre study was conducted from May to October 2022 across five centers in India. A total of 346 subjects were randomized to receive two doses of either the test vaccine (Vaxiflu-4, Zydus Lifesciences Limited; n = 174) or the reference vaccine (Fluarix Tetra, GlaxoSmithKline; n = 172). The primary objective was to compare immunogenicity using seroprotection rate, seroconversion rate, and geometric mean titers (GMTs) against four vaccine strains. Safety profiles were also compared. Both vaccines demonstrated non-inferiority, with seroprotection rates over 95%, seroconversion rates above 90%, and significant GMT increases. Adverse events (AEs) were similar for both vaccines, including pain at the injection site, erythema, swelling, and pyrexia. The test vaccine, Vaxiflu-4, showed non-inferiority in terms of immunogenicity and safety when compared with reference vaccine, Fluarix Tetra (Clinical trial registry number: CTRI/2022/05/042514).
Keywords: Immunogenicity; Influenza; pediatric vaccination; safety profile; tetravalent inactivated vaccine.